Literature DB >> 15064631

Timing of human insulin-like growth factor-1 gene transfer in reinnervating laryngeal muscle.

Hideki Nakagawa1, Akihiro Shiotani, Bert W O'Malley, Michael E Coleman, Paul W Flint.   

Abstract

OBJECTIVES/HYPOTHESIS: The authors have designed a rat laryngeal paralysis model to study gene transfer strategies using a muscle-specific expression system to enhance local delivery of human insulin-like growth factor-1 (hIGF-1). In preliminary studies, a nonviral vector containing the alpha-actin promoter and human hIGF-1 sequence produced both neurotrophic and myotrophic effects 1 month after single injection of plasmid formulation into paralyzed rat thyroarytenoid muscle in vivo. Based on these findings, it is hypothesized that the effects of hIGF-1 will enhance the results of laryngeal muscle innervation procedures. The timing of gene delivery relative to nerve repair is likely to be important, to optimize the results. STUDY
DESIGN: Prospective analysis.
METHODS: The effects of nonviral gene transfer for the delivery of hIGF-1 were evaluated in rats treated immediately following recurrent laryngeal nerve transection and repair and in rats receiving a delayed treatment schedule, 30 days after nerve transection and repair. Gene transfer efficiency was determined using polymerase chain reaction and reverse transcriptase-polymerase chain reaction techniques. Muscle fiber diameter, motor endplate length, and percentage of motor endplates with nerve contact were examined to assess hIGF-1 trophic effects.
RESULTS: Compared with reinnervated untreated control samples, both early and delayed hIGF-1 transfer resulted in significant increase in muscle fiber diameter. Motor endplate length was significantly decreased and nerve/motor endplate contact was significantly increased following delayed gene transfer, but not after early treatment.
CONCLUSION: We infer from results of the study that delayed hIGF-1 gene transfer delivered by a single intramuscular injection will enhance the process of muscle reinnervation. The clinical relevance of these findings supports the future application of gene therapy using nonviral vectors for management of laryngeal paralysis and other peripheral nerve injuries.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15064631     DOI: 10.1097/00005537-200404000-00024

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  4 in total

1.  Otolaryngology-head and neck surgery at Johns Hopkins: The first 100 years (1914-2014).

Authors:  Howard W Francis; Ira Papel; Ioan Lina; Wayne Koch; David Tunkel; Paul Fuchs; Sandra Lin; David Kennedy; Robert Ruben; Fred Linthicum; Bernard Marsh; Simon Best; John Carey; Andrew Lane; Patrick Byrne; Paul Flint; David W Eisele
Journal:  Laryngoscope       Date:  2015-08-22       Impact factor: 3.325

2.  Neurotrophic factor-secreting autologous muscle stem cell therapy for the treatment of laryngeal denervation injury.

Authors:  Stacey L Halum; Bryan McRae; Khadijeh Bijangi-Vishehsaraei; Kelly Hiatt
Journal:  Laryngoscope       Date:  2012-09-10       Impact factor: 3.325

3.  Reconstructive procedures for impaired upper airway function: laryngeal respiration.

Authors:  Andreas Müller
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

Review 4.  Gene Therapy for Recurrent Laryngeal Nerve Injury.

Authors:  Koji Araki; Hiroshi Suzuki; Kosuke Uno; Masayuki Tomifuji; Akihiro Shiotani
Journal:  Genes (Basel)       Date:  2018-06-25       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.